An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 23-valent pneumococcal vaccine.
- Who it may be relevant to
- Registry conditions: LUNG CANCER. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
Overview
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Interventions
- Biological 23-valent pneumococcal vaccine
Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
Primary outcome measures
- The incidence of pneumonia at 12 months [Time frame: 12 months]
- Incidence of pneumonia [Time frame: 24 months]
Secondary outcome measures (1)
- Survival rate [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Male or female patients >=18 years of age;
- Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
- Never received pneumococcal vaccine
Exclusion criteria
Patients having other factors that preventing researchers from enrollment them.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07142057 · 23V-PNEUMO-LC